YLF-466DCAS# 1273323-67-3 |
- Hydroxyfasudil
Catalog No.:BCC1635
CAS No.:105628-72-6
- chroman 1
Catalog No.:BCC1480
CAS No.:1273579-40-0
- Y-27632 dihydrochloride
Catalog No.:BCC1273
CAS No.:129830-38-2
- H-1152
Catalog No.:BCC1615
CAS No.:451462-58-1
- H-1152 dihydrochloride
Catalog No.:BCC1616
CAS No.:871543-07-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1273323-67-3 | SDF | Download SDF |
| PubChem ID | 51033997 | Appearance | Powder |
| Formula | C29H20ClNO3 | M.Wt | 465.93 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | C24 | ||
| Solubility | DMSO : ≥ 100 mg/mL (214.62 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 3-[[(3E)-3-[(4-chlorophenyl)-phenylmethylidene]-2-oxoindol-1-yl]methyl]benzoic acid | ||
| SMILES | C1=CC=C(C=C1)C(=C2C3=CC=CC=C3N(C2=O)CC4=CC=CC(=C4)C(=O)O)C5=CC=C(C=C5)Cl | ||
| Standard InChIKey | BPBOVHROVFJFAH-CYYJNZCTSA-N | ||
| Standard InChI | InChI=1S/C29H20ClNO3/c30-23-15-13-21(14-16-23)26(20-8-2-1-3-9-20)27-24-11-4-5-12-25(24)31(28(27)32)18-19-7-6-10-22(17-19)29(33)34/h1-17H,18H2,(H,33,34)/b27-26+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | YLF-466D is a newly developed AMPK activator, which inhibits platelet aggregation.In Vitro:The effect of YLF-466D on platelet AMPK and aggregation are examined to test whether YLF-466D can stimulate AMPK in platelets and thereby suppress aggregation. Platelet AMPK is activated by YLF-466D, which is confirmed with activation-dependent phosphorylation at Thr172. Consistent with this result, YLF-466D inhibits platelet aggregation induced by thrombin. Such inhibition is observed in the aggregation elicited by ADP and collagen as well as thrombin, indicating that the antiaggregatory effect of YLF-466D is not platelet-agonist specific but common, regardless of agonist type. All the effects on AMPK and aggregation are concentration-dependent with the highest efficacy at 150 μM. IC50 against thrombin-, ADP- and collagen-induced aggreation are approximately 84, 55 and 87 μM, respectively[1]. References: | |||||
YLF-466D Dilution Calculator
YLF-466D Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1462 mL | 10.7312 mL | 21.4625 mL | 42.9249 mL | 53.6561 mL |
| 5 mM | 0.4292 mL | 2.1462 mL | 4.2925 mL | 8.585 mL | 10.7312 mL |
| 10 mM | 0.2146 mL | 1.0731 mL | 2.1462 mL | 4.2925 mL | 5.3656 mL |
| 50 mM | 0.0429 mL | 0.2146 mL | 0.4292 mL | 0.8585 mL | 1.0731 mL |
| 100 mM | 0.0215 mL | 0.1073 mL | 0.2146 mL | 0.4292 mL | 0.5366 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
YLF-466D is an allosteric AMPK activator.
- PACAP 1-27
Catalog No.:BCC5726
CAS No.:127317-03-7
- Zamifenacin fumarate
Catalog No.:BCC7418
CAS No.:127308-98-9
- BRL 37344, sodium salt
Catalog No.:BCC6860
CAS No.:127299-93-8
- Balofloxacin
Catalog No.:BCC4892
CAS No.:127294-70-6
- Sitafloxacin
Catalog No.:BCC5164
CAS No.:127254-12-0
- Intermedin B
Catalog No.:BCN7317
CAS No.:127214-87-3
- Bisacurone C
Catalog No.:BCN7316
CAS No.:127214-86-2
- (3S,4S)-3-(Boc-amino)-4-methylpyrrolidine
Catalog No.:BCC4015
CAS No.:127199-54-6
- KN-62
Catalog No.:BCC3602
CAS No.:127191-97-3
- 7-(2'-Deoxyadenosin-N6-yl)aristolactam I
Catalog No.:BCN2559
CAS No.:127191-86-0
- 4-O-Demethylkadsurenin D
Catalog No.:BCN6649
CAS No.:127179-70-8
- MI-2
Catalog No.:BCC1746
CAS No.:1271738-62-5
- 2-Chloromethyl-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine hydrochloride
Catalog No.:BCC8569
CAS No.:127337-60-4
- Rebaudioside G
Catalog No.:BCN7860
CAS No.:127345-21-5
- Coclauril
Catalog No.:BCN6150
CAS No.:127350-68-9
- chroman 1
Catalog No.:BCC1480
CAS No.:1273579-40-0
- Odoroside A
Catalog No.:BCC8224
CAS No.:12738-19-1
- Y-27152
Catalog No.:BCC7254
CAS No.:127408-30-4
- Y-26763
Catalog No.:BCC7253
CAS No.:127408-31-5
- Calystegine B2
Catalog No.:BCN1879
CAS No.:127414-85-1
- Calystegine B1
Catalog No.:BCN1882
CAS No.:127414-86-2
- Conantokin-T
Catalog No.:BCC5977
CAS No.:127476-26-0
- VU 0360223
Catalog No.:BCC6159
CAS No.:1274859-33-4
- CNX1351
Catalog No.:BCC6375
CAS No.:1276105-89-5
Antiplatelet effect of a newly developed AMP-activated protein kinase activator YLF-466D.[Pubmed:25913239]
Eur J Pharmacol. 2015 Aug 5;760:81-7.
AMP-activated protein kinase (AMPK) acts as a major regulator of cellular energy homeostasis. In platelets, AMPK activation stimulates endothelial nitric oxide synthase (eNOS) and its downstream signaling, and thereby inhibits platelet aggregation. In this study, a newly developed AMPK activator 3-[[(3E)-3-[(4-chlorophenyl)phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-1-yl]meth yl]-benzoic acid (YLF-466D) was tested for its antiplatelet activity. Treatment of isolated platelets with YLF-466D resulted in AMPK activation in a concentration-dependent manner in a range of 50-150 muM. Under the same experimental condition, YLF-466D effectively inhibited aggregation induced by platelet agonists including thrombin, ADP and collagen. Such AMPK activation and aggregation inhibition were abolished by pretreatment with the AMPK inhibitors compound C (CC) and ara-A, indicating that antiaggregatory effect of YLF-466D is mediated by AMPK. YLF-466D induced an activation-dependent eNOS phosphorylation at Ser1177, an elevation of cyclic nucleotides cGMP and cAMP, and subsequent phosphorylation of vasodilator-stimulated phosphoprotein (VASP) at Ser239 and Ser157. All these events were prevented by CC and ara-A. In addition to isolated platelets, YLF-466D attenuated whole blood aggregation induced by collagen. Taken together, YLF-466D is capable of inhibiting platelet aggregation by activating AMPK and its downstream eNOS-cGMP-PKG signaling axis. This study reconfirms the antiplatelet activity of AMPK activators and suggests the potential application of YLF-466D to antiplatelet therapy, although the in vivo and clinical validation remains to be assessed.
